PHF19 and Akt control the switch between proliferative and invasive states in melanoma
出版年份 2012 全文链接
标题
PHF19 and Akt control the switch between proliferative and invasive states in melanoma
作者
关键词
-
出版物
CELL CYCLE
Volume 11, Issue 8, Pages 1634-1645
出版商
Informa UK Limited
发表日期
2012-04-11
DOI
10.4161/cc.20095
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Plasticity of melanoma cells induced by neural cell crest conditions and three-dimensional growth
- (2012) Stephanie Ghislin et al. MELANOMA RESEARCH
- Functional characterization of human Polycomb-like 3 isoforms identifies them as components of distinct EZH2 protein complexes
- (2011) Gaylor Boulay et al. BIOCHEMICAL JOURNAL
- Expression analysis and molecular targeting of cyclin-dependent kinases in advanced melanoma
- (2011) Christopher Abdullah et al. CELL CYCLE
- Characterization of human melanoma cell lines and melanocytes by proteome analysis
- (2011) Emilia Caputo et al. CELL CYCLE
- The proliferation rate paradox in antimitotic chemotherapy
- (2011) Timothy J. Mitchison MOLECULAR BIOLOGY OF THE CELL
- Mitf is the key molecular switch between mouse or human melanoma initiating cells and their differentiated progeny
- (2011) Y Cheli et al. ONCOGENE
- Junctional adhesion molecules are required for melanoma cell lines transendothelial migration in vitro
- (2011) Stephanie Ghislin et al. Pigment Cell & Melanoma Research
- GLI2 and M-MITF transcription factors control exclusive gene expression programs and inversely regulate invasion in human melanoma cells
- (2011) Delphine Javelaud et al. Pigment Cell & Melanoma Research
- Differential LEF1 and TCF4 expression is involved in melanoma cell phenotype switching
- (2011) Ossia M. Eichhoff et al. Pigment Cell & Melanoma Research
- Melanoma Spheroids Grown Under Neural Crest Cell Conditions Are Highly Plastic Migratory/Invasive Tumor Cells Endowed with Immunomodulator Function
- (2011) Kiran Ramgolam et al. PLoS One
- A Switch from Canonical to Noncanonical Wnt Signaling Mediates Drug Resistance in Colon Cancer Cells
- (2011) Michael Bordonaro et al. PLoS One
- Cancer Statistics, 2010
- (2010) A. Jemal et al. CA-A CANCER JOURNAL FOR CLINICIANS
- A Temporarily Distinct Subpopulation of Slow-Cycling Melanoma Cells Is Required for Continuous Tumor Growth
- (2010) Alexander Roesch et al. CELL
- Cooperativity ofCdk4R24CandRasin melanoma development
- (2010) Rachna Chawla et al. CELL CYCLE
- Convergence between Wnt-β-catenin and EGFR signaling in cancer
- (2010) Tianhui Hu et al. Molecular Cancer
- CDK1-dependent phosphorylation of EZH2 suppresses methylation of H3K27 and promotes osteogenic differentiation of human mesenchymal stem cells
- (2010) Yongkun Wei et al. NATURE CELL BIOLOGY
- Cancer stem cells versus phenotype-switching in melanoma
- (2010) Keith S. Hoek et al. Pigment Cell & Melanoma Research
- The PTEN-AKT3 signaling cascade as a therapeutic target in melanoma
- (2009) SubbaRao V. Madhunapantula et al. Pigment Cell & Melanoma Research
- In vivo Switching of Human Melanoma Cells between Proliferative and Invasive States
- (2008) K. S. Hoek et al. CANCER RESEARCH
- Role of ING4 in human melanoma cell migration, invasion and patient survival
- (2008) Jun Li et al. CARCINOGENESIS
- The ING gene family in the regulation of cell growth and tumorigenesis
- (2008) Andrew H. Coles et al. JOURNAL OF CELLULAR PHYSIOLOGY
- Chromatin immunoprecipitation (ChIP) coupled to detection by quantitative real-time PCR to study transcription factor binding to DNA in Caenorhabditis elegans
- (2008) Arnab Mukhopadhyay et al. Nature Protocols
- Downregulation of EZH2 decreases growth of estrogen receptor-negative invasive breast carcinoma and requires BRCA1
- (2008) M E Gonzalez et al. ONCOGENE
- The polycomb group protein EZH2 regulates actin polymerization in human prostate cancer cells
- (2007) R.J. Bryant et al. PROSTATE
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started